Buy Generic Avelox (Moxifloxacin) from India! Safety & Guarantee Shipping to United Kingdom, United States, Australia!
Active substance Moxifloxacin (C21H24FN3O4)
US Brand Avelox, Avalox, and Avelon
IN Brand Moxif / Talemox
Manufacturing by Torent Pharma, India
Strength 400mg
Form release Table
Estimated shipping time 7 – 18 days (Depending from the Country)
Availability, Prices & Order through request form
Make request

 

DescriptionDosageSide Effects

In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. In the US, the marketing approval does not contain these restrictions, though the label contains prominent warnings against skin reactions.

Avelox (moxifloxacin) was launched in the United States in 1999 and is marketed in more than 80 countries worldwide. In the United States, Avelox is marketed by Bayer’s partner Merck.

400 mg orally or IV every 24 hours for 7 to 14 days

400 mg orally or IV every 24 hours

Duration of therapy:
-Complicated infections: 7 to 21 days
-Uncomplicated infections: 7 days

400 mg orally or IV every 24 hours

Duration of therapy:
-Complicated infections: 7 to 21 days
-Uncomplicated infections: 7 days

Uses: For the treatment of complicated skin and skin structure infections due to susceptible isolates of methicillin-susceptible S aureus, Escherichia coli, K pneumoniae, or Enterobacter cloacae; for the treatment of uncomplicated skin and skin structure infections due to susceptible isolates of methicillin-susceptible S aureus or S pyogenes

Rare but serious adverse effects that may occur as a result of moxifloxacin therapy include irreversible peripheral neuropathy, spontaneous tendon rupture and tendonitis, hepatitis, psychiatric effects (hallucinations, depression), torsades de pointes, Stevens-Johnson syndrome and Clostridium difficile-associated disease, and photosensitivity/phototoxicity reactions.

Several reports suggest the use of moxifloxacin may lead to uveitis.